212 related articles for article (PubMed ID: 7341283)
1. Differential induction of antipyrine metabolism by rifampicin.
Toverud EL; Boobis AR; Brodie MJ; Murray S; Bennett PN; Whitmarsh V; Davies DS
Eur J Clin Pharmacol; 1981; 21(2):155-60. PubMed ID: 7341283
[TBL] [Abstract][Full Text] [Related]
2. Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig.
van den Broek JM; Teunissen MW; Breimer DD
Drug Metab Dispos; 1981; 9(6):541-4. PubMed ID: 6120813
[TBL] [Abstract][Full Text] [Related]
3. Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis.
Teunissen MW; Bakker W; Meerburg-Van der Torren JE; Breimer DD
Br J Clin Pharmacol; 1984 Nov; 18(5):701-6. PubMed ID: 6508979
[TBL] [Abstract][Full Text] [Related]
4. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.
Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C
Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393
[TBL] [Abstract][Full Text] [Related]
5. Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine.
Breimer DD; Zilly W; Richter E
Clin Pharmacol Ther; 1977 Apr; 21(4):470-81. PubMed ID: 849678
[TBL] [Abstract][Full Text] [Related]
6. The effect of antipyrine and rifampin on the metabolism of diazepam.
Ohnhaus EE; Brockmeyer N; Dylewicz P; Habicht H
Clin Pharmacol Ther; 1987 Aug; 42(2):148-56. PubMed ID: 3608348
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.
Boobis AR; Brodie MJ; Kahn GC; Toverud EL; Blair IA; Murray S; Davies DS
Br J Clin Pharmacol; 1981 Dec; 12(6):771-7. PubMed ID: 7340879
[TBL] [Abstract][Full Text] [Related]
8. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.
Engel G; Hofmann U; Heidemann H; Cosme J; Eichelbaum M
Clin Pharmacol Ther; 1996 Jun; 59(6):613-23. PubMed ID: 8681486
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of enzyme induction on antipyrine metabolite formation.
Danhof M; Verbeek RM; van Boxtel CJ; Boeijinga JK; Breimer DD
Br J Clin Pharmacol; 1982 Mar; 13(3):379-86. PubMed ID: 7059438
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects.
Perucca E; Grimaldi R; Frigo GM; Sardi A; Mönig H; Ohnhaus EE
Eur J Clin Pharmacol; 1988; 34(6):595-9. PubMed ID: 2901960
[TBL] [Abstract][Full Text] [Related]
11. The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.
Bach D; Blevins R; Kerner N; Rubenfire M; Edwards DJ
Br J Clin Pharmacol; 1986 Jun; 21(6):655-9. PubMed ID: 3741715
[TBL] [Abstract][Full Text] [Related]
12. Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative.
Vital Durand D; Hampden C; Boobis AR; Park BK; Davies DS
Br J Clin Pharmacol; 1986 Jan; 21(1):1-7. PubMed ID: 3947503
[TBL] [Abstract][Full Text] [Related]
13. Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment.
Danhof M; Krom DP; Breimer DD
Xenobiotica; 1979 Nov; 9(11):695-702. PubMed ID: 119355
[TBL] [Abstract][Full Text] [Related]
14. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.
Shaw PN; Houston JB; Rowland M; Hopkins K; Thiercelin JF; Morselli PL
Br J Clin Pharmacol; 1985 Dec; 20(6):611-8. PubMed ID: 4091993
[TBL] [Abstract][Full Text] [Related]
15. Effect of chloroquine and primaquine on antipyrine metabolism.
Back DJ; Purba HS; Park BK; Ward SA; Orme ML
Br J Clin Pharmacol; 1983 Nov; 16(5):497-502. PubMed ID: 6639836
[TBL] [Abstract][Full Text] [Related]
16. Antipyrine clearance and metabolite formation in children with congenital adrenal hyperplasia.
Teunissen MW; Bruining GJ; De Jongh BM; Tenkate-Westerhof EW; Breimer DD
Br J Clin Pharmacol; 1985 Dec; 20(6):703-6. PubMed ID: 4092001
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of antipyrine and sulphadimidine in dwarf goats: effects of the enzyme-inducing agents phenobarbital, troleandomycin and rifampicin.
Natsuhori M; Witkamp RF; Van 't Klooster GA; Van Miert AS
Xenobiotica; 1992 Nov; 22(11):1243-50. PubMed ID: 1492417
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of 3-methylcholanthrene and phenobarbitone treatment on the oxidative metabolism of antipyrine in vitro by microsomal fractions of rat liver.
Kahn GC; Boobis AR; Murray S; Davies DS
Xenobiotica; 1982 Aug; 12(8):509-16. PubMed ID: 7147996
[TBL] [Abstract][Full Text] [Related]
19. Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state.
Teunissen MW; De Leede LG; Boeijinga JK; Breimer DD
J Pharmacol Exp Ther; 1985 Jun; 233(3):770-5. PubMed ID: 4009489
[TBL] [Abstract][Full Text] [Related]
20. Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans.
Abernethy DR; Egan JM; Dickinson TH; Carrum G
J Pharmacol Exp Ther; 1988 Mar; 244(3):994-9. PubMed ID: 3252045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
